


Participant Flow



Baseline Characteristics

| | All eligible patients | | | | Per-protocol patients | | | |
|--------------------------------|-------------------------------------|-------|--------------------------------|-------|-------------------------------------|-------|--------------------------------|-------|
| | Intervention practices (n=5,060) | | Control practices (n=5,363) | | Intervention practices (n=2,331) | | Control practices (n=2,326) | |
| | n | % | n | % | n | % | n | % |
| Demography | | | | | | | | |
| Age categories | | | | | | | | |
| 18-49 years | 291 | 5.8% | 312 | 5.8% | 103 | 4.4% | 150 | 6.4% |
| 50-59 years | 704 | 13.9% | 822 | 15.3% | 309 | 13.3% | 364 | 15.6% |
| 60-69 years | 1182 | 23.4% | 1304 | 24.3% | 544 | 23.3% | 580 | 24.9% |
| 70-79 years | 1514 | 29.9% | 1519 | 28.3% | 756 | 32.4% | 635 | 27.3% |
| 80+ years | 1369 | 27.1% | 1406 | 26.2% | 619 | 26.6% | 597 | 25.7% |
| Sex | | | | | | | | |
| Male | 2297 | 45.4% | 2364 | 44.1% | 1102 | 47.3% | 1029 | 44.2% |
| Female | 2763 | 54.6% | 2999 | 55.9% | 1229 | 52.7% | 1297 | 55.8% |
| Ethnicity | | | | | | | | |
| White | 4603 | 91.0% | 4582 | 85.4% | 2142 | 91.9% | 1814 | 78.0% |
| Black | 38 | 0.8% | 180 | 3.4% | 17 | 0.7% | 148 | 6.4% |
| Asian | 56 | 1.1% | 213 | 4.0% | 17 | 0.7% | 173 | 7.4% |
| Mixed | 51 | 1.0% | 45 | 0.8% | 22 | 0.9% | 24 | 1.0% |
| Other | 3 | 0.1% | 8 | 0.1% | 2 | 0.1% | 6 | 0.3% |
| Missing | 309 | 6.1% | 335 | 6.2% | 131 | 5.6% | 161 | 6.9% |
| IMD quintiles | | | | | | | | |
| 1 | 1698 | 33.6% | 1886 | 35.2% | 805 | 34.5% | 979 | 42.1% |
| 2 | 958 | 18.9% | 967 | 18.0% | 516 | 22.1% | 422 | 18.1% |
| 3 | 933 | 18.4% | 838 | 15.6% | 454 | 19.5% | 385 | 16.6% |
| 4 | 874 | 17.3% | 936 | 17.5% | 403 | 17.3% | 291 | 12.5% |
| 5 | 594 | 11.7% | 732 | 13.6% | 153 | 6.6% | 247 | 10.6% |
| Missing | 3 | 0.1% | 4 | 0.1% | 0 | 0.0% | 2 | 0.1% |
| Number of long-term conditions | | | | | | | | |

| | | | | | | | | |
|-----------------------------------|------|-------|------|-------|------|-------|------|-------|
| 3 | 3326 | 65.7% | 3485 | 65.0% | 1494 | 64.1% | 1463 | 62.9% |
| 4 | 1335 | 26.4% | 1482 | 27.6% | 626 | 26.9% | 684 | 29.4% |
| 5+ | 399 | 7.9% | 396 | 7.4% | 211 | 9.1% | 179 | 7.7% |
| Long term conditions*: | | | | | | | | |
| CVD | 4656 | 92.0% | 4976 | 92.8% | 2186 | 93.8% | 2143 | 92.1% |
| CHD | 1225 | 24.2% | 1298 | 24.2% | 607 | 26.0% | 579 | 24.9% |
| Atrial fibrillation | 872 | 17.2% | 869 | 16.2% | 436 | 18.7% | 374 | 16.1% |
| Hypertension | 3950 | 78.1% | 4254 | 79.3% | 1866 | 80.1% | 1840 | 79.1% |
| Heart failure | 614 | 12.1% | 671 | 12.5% | 309 | 13.3% | 305 | 13.1% |
| PAD | 357 | 7.1% | 317 | 5.9% | 174 | 7.5% | 121 | 5.2% |
| CKD | 1486 | 29.4% | 1630 | 30.4% | 738 | 31.7% | 657 | 28.2% |
| Respiratory disease | 2725 | 53.9% | 2937 | 54.8% | 1303 | 55.9% | 1256 | 54.0% |
| COPD | 1332 | 26.3% | 1455 | 27.1% | 686 | 29.4% | 590 | 25.4% |
| Asthma | 1714 | 33.9% | 1858 | 34.6% | 774 | 33.2% | 813 | 35.0% |
| Mental health (SMI or depression) | 2873 | 56.8% | 2994 | 55.8% | 1182 | 50.7% | 1256 | 54.0% |
| Depression | 2737 | 54.1% | 2840 | 53.0% | 1139 | 48.9% | 1183 | 50.9% |
| Severe mental illness (QOF) | 284 | 5.6% | 333 | 6.2% | 101 | 4.3% | 145 | 6.2% |
| Dementia or severe frailty | 1442 | 28.5% | 1355 | 25.3% | 662 | 28.4% | 705 | 30.3% |
| Dementia | 414 | 8.2% | 461 | 8.6% | 147 | 6.3% | 192 | 8.3% |
| Severe frailty | 1224 | 24.2% | 1094 | 20.4% | 590 | 25.3% | 615 | 26.4% |
| Stroke | 1470 | 29.1% | 1584 | 29.5% | 686 | 29.4% | 669 | 28.8% |
| Diabetes | 3176 | 62.8% | 3421 | 63.8% | 1651 | 70.8% | 1513 | 65.0% |
| Epilepsy | 431 | 8.5% | 536 | 10.0% | 144 | 6.2% | 235 | 10.1% |
| Learning disability register | 172 | 3.4% | 196 | 3.7% | 57 | 2.4% | 82 | 3.5% |
| Rheumatoid arthritis | 416 | 8.2% | 425 | 7.9% | 204 | 8.8% | 184 | 7.9% |

Outcome Measures

Personalised Care and Support Plan comparisons

| Patient cohort | Pre-implementation | Post-implementation | DID effect (effect of period in the implementation group over and above any effect of implementation or period alone) | | | |
|--|--------------------|---------------------|---|---------|--|---------|
| | n (%) | n (%) | Odds ratio (95% CI) | p-value | Mean difference in percentage (95% CI) | p-value |
| Implementation practices (n=5060) | 132 (2.6%) | 268 (5.3%) | | | | |
| Control practices (n=5363) | 711 (13.3%) | 790 (14.7%) | 1.96 (1.47 to 2.63) | <0.001 | 1.21 (-4.64 to 7.07) | 0.684 |

Adverse Events

There were no adverse events associated with this study.